Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05036447
Other study ID # STYRK DM1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 14, 2021
Est. completion date April 30, 2023

Study information

Verified date November 2023
Source Norwegian School of Sport Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the response after one bout of moderate-heavy resistance exercise in patients suffering from Myotonic Dystrophy type 1. There is still doubt about if these patients could benefit from resistance exercise, or if this mode of exercise is detrimental to their mobility and health. We aim to monitor the subjects during the recovery phase and investigate recovery in several ways.


Description:

Myotonic dystrophy type 1 (DM1) is an autosomal, dominantly inherited, muscular disease and the most common muscular dystrophy amongst adults. The disease is characterized by progressive myopathy and myotonia, first evident in the distal parts of the body: calves and forearms, further progressing towards proximal parts. A recent review by Voet and co-workers (2013) concludes that exercise is safe for DM1-patients, and based on our current knowledge, DM1-patients should be able to gain positive adaptations from exercise. However, the physiological outcomes of an exercise stimulus are not well studied in this population and because of alterations in important Ca2+ handling systems the recovery processes might be significantly different from healthy muscles. The aim of this study is to investigate the acute responses to moderate-heavy resistance exercise in DM1-patients. We aim to establish a timeline for recovery of muscle strength, measured as maximal voluntary contraction. In line with this, we want to investigate if any muscular damage has occurred with both direct and indirect measures, and possible mechanisms leading to muscle damage, i.e. impaired Ca2+ handling.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date April 30, 2023
Est. primary completion date April 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Confirmed Myotonic Dystrophy type 1-diagnosis Exclusion Criteria: - Non-ambulatory - Injuries to muscle-skeletal-system that prevents resistance exercise - Severe affection of the cardiovascular system - Cognitive affection - Lives more than one hour from test site

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Moderate-Heavy Resistance Exercise
Leg press: 3 x 8 repetitions at 75% of 1 repetition maximum, 3 minutes rest between sets. Knee extension: 3 x 6 repetitions at 85% of 1 repetition maximum, 3 minutes rest between sets.

Locations

Country Name City State
Norway Norwegian School of Sport Sciences Oslo

Sponsors (6)

Lead Sponsor Collaborator
Norwegian School of Sport Sciences Maastricht University, Oslo University Hospital, University of Copenhagen, University of Oslo, University of Southern Denmark

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in muscle damage Myofibrillar disruption and necrosis observed in muscle tissue samples from m. vastus lateralis with electron microscopy Baseline and 27 hours after final session of resistance exercise
Other Change in muscle regeneration Appearance of macrophages, satellite cell localization, and disruption of membrane in single muscle fibers and cross-sections using confocal microscopy Baseline and 27 hours after final session of resistance exercise
Other Change in calcium cycling Calcium cycling in muscle tissue samples from m. vastus lateralis Baseline and 27 hours after final session of resistance exercise
Other Change in contractile function Assessment of contractile function in single muscle fibers from m. vastus lateralis Baseline and 27 hours after final session of resistance exercise
Other Change in calcium-related protein abundances Levels of protein and phosphorylation status using Western blotting Baseline and 27 hours after final session of resistance exercise
Other Muscle fiber type Fiber type composition in samples from m. vastus lateralis Baseline
Other Muscle fiber type Fiber type composition in samples from m. vastus lateralis 27 hours after final session of resistance exercise
Other Change in heat shock proteins Localization and expression of heat shock proteins using Western blotting and Immunohistochemistry Baseline and 27 hours after final session of resistance exercise
Other Change in anabolic signaling Expression and phosphorylation status of central mediators in anabolic signaling pathways using Western blotting Baseline and 27 hours after final session of resistance exercise
Other Change in autophagy Expression and phosphorylation status of central mediators in pathways regulating muscle protein breakdown using Western blotting Baseline and 27 hours after final session of resistance exercise
Other Change in biomarkers of muscle damage Levels of serum Creatine kinase, Myoglobin, and Troponin I Baseline, and 3 hours, 24 hours, 48 hours, 71 hours, and 96 hours after exercise
Other Change in biomarker of muscle damage Level of titin-N fragment in urine Baseline, and 20 hours, 44 hours, 68 hours, and 92 hours after exercise
Other Change in Fatigue Electrical stimulation of m. vastus lateralis and m. vastus medialis at 10, 20, 50, and 80 Hz Baseline, and 1 hour after exercise
Other Change in muscle stiffness Muscle stiffness measured with shear wave elastography in static and dynamic conditions Baseline, and 50 minutes after exercise
Other Change in muscle soreness Subjective rating of muscle soreness using a visual analogue scale (0-10) Baseline, and 3 hours, 24 hours, 48 hours, and 71 hours after exercise
Other Change in muscle swelling Thickness of m. vastus lateralis using ultrasound B-mode Baseline, and 3 hours, 24 hours, 48 hours, and 71 hours after exercise
Primary Change in muscle strength Recovery of knee extension torque Baseline, and 5 minutes, 3 hours, 24 hours, 48 hours, and 71 hours after exercise
Secondary Muscle protein synthesis rate Rate of muscle protein synthesis in m. vastus lateralis between baseline and 27 hours after final session of resistance exercise Baseline and 27 hours after final session of resistance exercise
Secondary Muscle protein breakdown rate Rate of muscle protein breakdown in m. vastus lateralis between baseline and 27 hours after final session of resistance exercise Baseline and 27 hours after final session of resistance exercise
See also
  Status Clinical Trial Phase
Recruiting NCT02880735 - Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy N/A
Active, not recruiting NCT06089018 - Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy
Completed NCT05662150 - Low-frequency Repetitive Nerve Stimulation in Myotonic Dystrophy Type 1 N/A
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Completed NCT05027269 - Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients Phase 1/Phase 2
Completed NCT04712422 - Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1
Recruiting NCT05006924 - Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1
Recruiting NCT04656210 - Myotonic Dystrophy - Vascular and Cognition
Completed NCT04634682 - Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 N/A
Withdrawn NCT06270186 - Evaluation of Cognitive Functions in 20 Patients With Type 1 Myotonic Dystrophy With Virtual Reality Approach N/A
Not yet recruiting NCT06300307 - Study of ATX-01 in Participants With DM1 Phase 1/Phase 2
Completed NCT02729597 - Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study N/A
Recruiting NCT06138743 - Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Phase 1
Not yet recruiting NCT05532813 - Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease) Phase 3
Active, not recruiting NCT04886518 - Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Phase 2
Not yet recruiting NCT05865483 - Profile of Dysphagia in Myotonic Dystrophy Type 1 (DM1)
Recruiting NCT03424460 - Venous Thromboembolism in Myotonic Dystrophy Type 1 N/A
Completed NCT04001920 - Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1 N/A
Completed NCT02858908 - Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Phase 2
Completed NCT04018820 - Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1 N/A